Research Analysts’ Recent Ratings Changes for Bio-Rad Laboratories (BIO)

Several brokerages have updated their recommendations and price targets on shares of Bio-Rad Laboratories (NYSE: BIO) in the last few weeks:

  • 2/28/2018 – Bio-Rad Laboratories had its price target lowered by analysts at Wells Fargo & Co from $290.00 to $280.00. They now have an “outperform” rating on the stock.
  • 2/28/2018 – Bio-Rad Laboratories had its price target raised by analysts at Jefferies Group LLC to $325.00. They now have a “buy” rating on the stock.
  • 2/28/2018 – Bio-Rad Laboratories had its price target raised by analysts at Citigroup Inc to $325.00. They now have a “buy” rating on the stock.
  • 2/16/2018 – Bio-Rad Laboratories was downgraded by analysts at CL King from a “buy” rating to a “neutral” rating.

Bio-Rad Laboratories, Inc. (NYSE BIO) opened at $262.34 on Wednesday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $193.65 and a fifty-two week high of $279.59. The company has a quick ratio of 2.75, a current ratio of 3.93 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $7,737.79, a PE ratio of 68.86, a PEG ratio of 2.22 and a beta of 0.89.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.22. Bio-Rad Laboratories had a return on equity of 3.63% and a net margin of 5.31%. The firm had revenue of $620.43 million during the quarter, compared to analysts’ expectations of $618.89 million. research analysts anticipate that Bio-Rad Laboratories, Inc. will post 5.86 earnings per share for the current fiscal year.

In other news, CFO Christine A. Tsingos sold 4,980 shares of the company’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $249.40, for a total value of $1,242,012.00. Following the completion of the transaction, the chief financial officer now directly owns 7,283 shares in the company, valued at approximately $1,816,380.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 28.29% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc and related companies with's FREE daily email newsletter.

Leave a Reply